Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
Reichman
Lee B
LB
New Jersey Medical School National Tuberculosis Center, 225 Warren St., P.O. Box 1709, Newark, NJ 07101-1709, USA. reichmlb@umdnj.edu
Lardizabal
Alfred
A
Hayden
Christopher H
CH
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003365:Costs and Cost Analysis; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004641:Emigration and Immigration; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010349:Patient Compliance; D012293:Rifampin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy*; D014481:United States
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin